News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 14/08/2026 HKT			5-day change	1st Jan Change
15.84 ^USD	-0.69%		+0.83%	+1.02%

08-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT

All News

Mentions Relevance

08-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT
08-06	Monte Rosa Therapeutics: Q2 Earnings Snapshot	AQ
08-06	Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates	GL
07-31	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT
07-03	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
06-30	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
06-30	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000 Value Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000 Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Small Cap Comp Value Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2500 Value Benchmark	CI
06-03	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05-20	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
05-07	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Monte Rosa Therapeutics: Q1 Earnings Snapshot	AQ
05-07	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT
05-07	Monte Rosa Therapeutics : Corporate Presentation – May 2026	PU
05-07	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ